Company News

In a move set to bolster investor engagement across Australia's life sciences sector, AusBiotech has announced the appointment of Kerri Lee Sinclair as its new Head of Investment.

PYC Therapeutics (ASX:PYC) has achieved notable progress in its Phase 1a Single Ascending Dose clinical trial for its RNA-based therapeutic candidate, PYC-003, targeting autosomal dominant polycystic kidney disease.

Neuren Pharmaceuticals (ASX:NEU) has announced the addition of SYNGAP1-related disorder to the development pipeline for its investigational therapy NNZ-2591, marking another step in the company’s strategy to target rare, genetically defined neurodevelopmental disorders.

Noxopharm (ASX:NOX) has announced significant progress in its HERACLES trial for SOF-SKN, a promising new drug candidate for autoimmune diseases.

Syntara CEO Gary Phillips said, "We will use the FDA guidance to refine our clinical development plan for amsulostat and continue discussions with partners based on the FDA recommended path forward."

Leading science and technology company Merck has welcomed new expert guidance that will harmonise the tests used in the diagnosis and treatment of endocrine disorders in children across Australia and New Zealand.

Cartherics, a company developing off-the-shelf immune stem cell therapies with lead programs in ovarian cancer and endometriosis, has unveiled its new, state-of-the-art cleanroom facility for clinical-scale manufacturing of cell therapy products.

Queensland Deputy Premier Jarrod Bleijie has officially unveiled the name of Translational Research Institute’s Australian-first cGMP biomedical manufacturing facility, nearing completion next door to TRI at Woolloongabba.

“The FDA clearance and USA launch of trophon3 and trophon2 Plus mark an important milestone for Nanosonics. These innovations set a new benchmark in automated high-level disinfection and unlock significant growth opportunity through both new installed base and upgrades,” said Michael Kavanagh, Nanosonics CEO and President.

WEHI researchers have visualised a key protein complex in malaria parasites for the first time, uncovering a potential new target for next-generation vaccines that could help stop the disease from spreading.

Clinical-stage biotech company Noxopharm (ASX:NOX) has announced initial results from a US company testing assets from the Sofra technology platform.

"The FDA feedback positions Immutep to evaluate options for future collaborative clinical development paths to bring a new, effective and safe treatment option to this underserved patient population,” said Marc Voigt, CEO of Immutep.